NEUROCRINE BIOSCIENCES INC (NBIX) Stock Analyst Ratings
NASDAQ:NBIX • US64125C1099
124.12 USD
+1.02 (+0.83%)
At close: Feb 13, 2026
124 USD
-0.12 (-0.1%)
After Hours: 2/13/2026, 9:29:07 PM
ChartMill assigns a Buy % Consensus number of 84% to NBIX. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 182.16. This target is 46.76% above the current price.
- NBIX was analyzed by 35 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about NBIX.
- In the previous month the buy percentage consensus was at a similar level.
- NBIX was analyzed by 35 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-12 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2026-02-12 | Needham | Maintains | Buy -> Buy |
| 2026-02-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-12 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-23 | UBS | Maintains | Buy -> Buy |
| 2026-01-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-01-08 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-08 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-12-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-12 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-12-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-05 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-30 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-29 | Needham | Maintains | Buy -> Buy |
| 2025-10-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-29 | Stifel | Maintains | Buy -> Buy |
| 2025-10-29 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-10-29 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-29 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-21 | Citigroup | Initiate | Buy |
| 2025-10-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-09 | UBS | Maintains | Buy -> Buy |
| 2025-09-22 | Needham | Maintains | Buy -> Buy |
| 2025-09-05 | RBC Capital | Maintains | Outperform -> Outperform |
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
Can you provide the average price target for NEUROCRINE BIOSCIENCES INC stock?
35 analysts have analysed NBIX and the average price target is 182.16 USD. This implies a price increase of 46.76% is expected in the next year compared to the current price of 124.12.
Can you provide the consensus rating for NEUROCRINE BIOSCIENCES INC stock?
The consensus rating for NEUROCRINE BIOSCIENCES INC (NBIX) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover NEUROCRINE BIOSCIENCES INC (NBIX) stock?
The number of analysts covering NEUROCRINE BIOSCIENCES INC (NBIX) is 35.